Chlorambucil

證據等級: L5

預測適應症: 10 個

Chlorambucil: From Chronic Lymphocytic Leukemia to CLL/SLL with IgHV Somatic Hypermutation

One-Sentence Summary

Chlorambucil is a nitrogen mustard alkylating agent with a decades-long history as first-line treatment for chronic lymphocytic leukemia (CLL) and low-grade non-Hodgkin lymphomas. The TxGNN model predicts it may be effective for CLL/SLL with immunoglobulin heavy chain variable-region gene (IgHV) somatic hypermutation — a molecularly distinct, more favourable-prognosis subtype of CLL — with a prediction score of 99.72%. However, the evidence pack contains no clinical trials and no literature specific to this molecular subtype, yielding an Evidence Level of L5.

Quick Overview

Item	Content
Original Indication	Chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (based on known clinical use; no regulatory record available in Denmark)
Predicted New Indication	CLL/SLL with IgHV somatic hypermutation (mutated IGHV subtype)
TxGNN Prediction Score	99.72%
Evidence Level	L5
Denmark Market Status	Not marketed (no marketing authorisation on file)
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the evidence pack. Based on established clinical knowledge, chlorambucil is a bifunctional alkylating agent belonging to the nitrogen mustard class. It forms interstrand and intrastrand DNA cross-links, blocking DNA replication and transcription, and ultimately inducing apoptosis in proliferating lymphocytes. This mechanism has made it effective against indolent lymphoid malignancies for over 50 years.

The predicted new indication — CLL/SLL with mutated IgHV (somatic hypermutation of the immunoglobulin heavy chain variable-region gene) — is not a separate disease but a molecularly defined subgroup within CLL. Patients with mutated IGHV have a significantly more indolent disease course, lower genomic complexity, and historically demonstrated better depth and duration of response to chlorambucil-based regimens compared with their unmutated IGHV counterparts. The TxGNN model’s top prediction therefore reflects a biologically plausible subtype-refinement of chlorambucil’s established indication rather than a wholly novel therapeutic use.

The landmark Phase 3 RESONATE-2 trial (PMID 36672456) explicitly used chlorambucil as the comparator arm for previously untreated CLL/SLL in patients aged ≥65 years, confirming its continued relevance as a benchmark therapy in this population. The model’s prediction that the mutated IGHV subgroup may be a preferential target aligns with published prognostic data showing mutated IGHV as a predictor of superior outcomes with conventional chemotherapy.

Clinical Trial Evidence

Currently no related clinical trials registered for CLL/SLL with IgHV somatic hypermutation specifically.

Literature Evidence

No publications identified specifically combining chlorambucil with CLL/SLL with IgHV somatic hypermutation.

Context note: The evidence pack identifies supporting literature under secondary predicted indications (pregerminal center CLL/SLL and primary pulmonary lymphoma), detailed below.

Supporting Evidence: Secondary Predicted Indications

The evidence pack lists several closely related predicted indications. Below is a consolidated summary of the available literature, which provides broader context for chlorambucil’s activity in B-cell lymphoid malignancies.

Pregerminal Center CLL/SLL (Rank 2, Score 99.72%)

PMID	Year	Type	Journal	Key Findings
12577769	2003	Review	Ned Tijdschr Geneeskd	Describes two molecular subtypes of CLL — pregerminal centre (unmutated IGHV) and post-germinal centre (mutated IGHV); argues for risk-adapted treatment; highlights that ~50% of stage A patients require treatment

Primary Pulmonary Lymphoma (Rank 7, Score 99.42%)

This indication has the strongest supporting literature in the evidence pack, with 16 publications including direct case reports and observational studies documenting chlorambucil use.

PMID	Year	Type	Journal	Key Findings
36672456	2023	RCT (Phase 3)	Cancers	RESONATE-2 ≥5-year follow-up: ibrutinib superior to chlorambucil in previously untreated CLL/SLL (≥65 years, no del(17p)); chlorambucil used as active comparator
19541720	2009	Observational cohort	Eur Respir J	Pulmonary MALT lymphoma: 63-case multicentre series; evaluates clinical characteristics, staging, and long-term outcomes
18603558	2008	Practice guidelines	Haematologica	Italian Society of Hematology guidelines for primary lung lymphomas; alkylating agents including chlorambucil listed as treatment options for low-grade subtypes
25452791	2015	Case report / Review	Exp Ther Med	Pulmonary MALT lymphoma in a 19-year-old; reviews diagnostic approach and treatment strategies including chemotherapy
3307632	1987	Phase II trial	Cancer Chemother	Chlorambucil 4–6 mg/day in 8 haematological malignancies including CLL and pseudolymphoma of the lung; partial remission achieved in CLL and pulmonary pseudolymphoma
3699123	1986	Case report	Eur J Respir Dis	Primary NHL of the lung with bilateral infiltrates; chlorambucil given for 5 months; patient achieved subsequent remission
6248988	1980	Case report	Sem Hop Paris	Primary lymphosarcoma of the lung secreting IgM; 3-year clinical remission maintained with continuous chlorambucil monotherapy
11289295	2001	Case report	Dis Colon Rectum	Simultaneous MALT lymphoma of colon and lung; treated with mitoxantrone and chlorambucil combination
11223743	2001	Case report	Respiration	Pulmonary MALT lymphoma in a common variable immunodeficiency patient; discusses treatment approach including alkylating agents
11483337	2001	Retrospective	Int J Radiat Oncol	Stage I/II MALT lymphoma across multiple organs treated with involved-field radiotherapy; establishes treatment benchmarks

Denmark Market Information

No marketing authorisations for chlorambucil are registered in the Laegemiddelstyrelsen database as of the data cutoff (2026-04-04).

Important note for Danish clinicians: Chlorambucil (brand name Leukeran, Aspen Pharma) holds marketing authorisations in several EU member states and has historically been available via centralised or national procedures. The absence of a record in this evidence pack may reflect a data gap rather than true non-availability. Direct verification with the Laegemiddelstyrelsen is required before any clinical consideration.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Alkylating agent (nitrogen mustard class, bifunctional)
Myelosuppression Risk	High — dose-limiting toxicities include neutropenia, thrombocytopenia, and anaemia; myelosuppression is cumulative and may be prolonged
Emetogenicity Classification	Low to moderate (oral tablet; generally well tolerated in this regard)
Monitoring Items	Full blood count with differential (CBC) before each course; liver function tests; renal function (eGFR); uric acid and LDH (tumour lysis risk at initiation)
Handling Protection	Oral solid dosage form; must be handled according to cytotoxic drug handling regulations (PPE required; tablets must not be crushed; disposal per hazardous waste protocols)

Safety Considerations

Detailed warnings and contraindication data are not available in this evidence pack. Please refer to the approved Summary of Product Characteristics (SmPC) for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top predicted indication — CLL/SLL with mutated IgHV — represents a molecular subtype of chlorambucil’s established historical indication rather than a genuinely novel use. The evidence pack returns zero clinical trials and zero dedicated literature for this specific subtype (L5), no marketing authorisation data for Denmark is on file, and critical safety data (SmPC warnings, contraindications, DDI profile) are absent. Furthermore, modern CLL treatment guidelines have largely displaced chlorambucil with BTK inhibitors and BCL-2 inhibitors for most patients, limiting the clinical relevance of further investigation unless specifically targeting a cost-sensitive, elderly, or comorbid population where chlorambucil retains a role.

To proceed, the following is needed:

Verify current Laegemiddelstyrelsen / EMA marketing authorisation status for chlorambucil (Leukeran) and obtain the approved Danish SmPC
Retrieve full safety data: TFDA/EMA label warnings and contraindications (Data Gap DG001) and DrugBank MOA entry (Data Gap DG002)
Conduct a targeted literature review of landmark CLL trials (RESONATE-2, CLL8, CLL10, COMPLEMENT-1) with IgHV mutation-stratified subgroup analyses to assess whether mutated IGHV patients derive quantifiably superior benefit from chlorambucil
Define the specific clinical niche (e.g., elderly patients with comorbidities unsuitable for intensive regimens) in which chlorambucil in the mutated IGHV subgroup would add value over current standard-of-care options
If proceeding to primary pulmonary lymphoma (rank 7), formalise evidence level for the existing case series and evaluate whether an investigator-initiated study is warranted given the absence of any registered trials
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.